ACAD
34.33
+0.5
+1.48%
AEMD
2.23
-0.04
-1.76%
APRI
1.13
+0.02
+1.80%
ARNA
1.34
-0.04
-2.90%
ATEC
2.03
-0.1
-4.69%
CNAT
8.36
-0.41
-4.68%
CRXM
0.195
+0.012
+6.47541%
CYTX
1.03
-0.04
-3.74%
DXCM
77.96
+0.03
+0.04%
GNMK
12.82
-0.06
-0.47%
HALO
13.94
-0.05
-0.36%
ILMN
184.86
+1.12
+0.61%
INNV
0.09
0.00
-1.10%
INO
6.29
-0.14
-2.18%
ISCO
1.75
+0.08
+4.48%
ISIS
57.56
0.00
0.00%
LGND
111.17
-0.02
-0.02%
LPTN
2.93
-0.08
-2.66%
MBVX
2.27
+0.06
+2.71%
MEIP
1.59
0.00
0.00%
MNOV
5.75
-0.07
-1.20%
MRTX
4.55
-0.22
-4.71%
MSTX
0.131
-0.007
-5.278%
NBIX
53.4
-0.19
-0.35%
NUVA
72.51
-0.3
-0.41%
ONCS
1.15
+0.01
+0.88%
ONVO
2.9
+0.01
+0.35%
OREX
3.37
-0.24
-6.65%
OTIC
13.35
-0.3
-2.20%
QDEL
24.17
+0.02
+0.08%
RCPT
231.96
0.00
0.00%
RGLS
1.55
-0.05
-3.13%
RMD
67.99
-4.86
-6.67%
SPHS
2.578
+0.028
+1.0863%
SRNE
1.95
-0.15
-7.14%
TROV
0.93
+0.02
+2.46%
VICL
2.36
+0.05
+2.16%
VOLC
18
0.00
0.00%
ZGNX
11
0.00
0.00%
ACAD
34.33
+0.5
+1.48%
AEMD
2.23
-0.04
-1.76%
APRI
1.13
+0.02
+1.80%
ARNA
1.34
-0.04
-2.90%
ATEC
2.03
-0.1
-4.69%
CNAT
8.36
-0.41
-4.68%
CRXM
0.195
+0.012
+6.47541%
CYTX
1.03
-0.04
-3.74%
DXCM
77.96
+0.03
+0.04%
GNMK
12.82
-0.06
-0.47%
HALO
13.94
-0.05
-0.36%
ILMN
184.86
+1.12
+0.61%
INNV
0.09
0.00
-1.10%
INO
6.29
-0.14
-2.18%
ISCO
1.75
+0.08
+4.48%
ISIS
57.56
0.00
0.00%
LGND
111.17
-0.02
-0.02%
LPTN
2.93
-0.08
-2.66%
MBVX
2.27
+0.06
+2.71%
MEIP
1.59
0.00
0.00%
MNOV
5.75
-0.07
-1.20%
MRTX
4.55
-0.22
-4.71%
MSTX
0.131
-0.007
-5.278%
NBIX
53.4
-0.19
-0.35%
NUVA
72.51
-0.3
-0.41%
ONCS
1.15
+0.01
+0.88%
ONVO
2.9
+0.01
+0.35%
OREX
3.37
-0.24
-6.65%
OTIC
13.35
-0.3
-2.20%
QDEL
24.17
+0.02
+0.08%
RCPT
231.96
0.00
0.00%
RGLS
1.55
-0.05
-3.13%
RMD
67.99
-4.86
-6.67%
SPHS
2.578
+0.028
+1.0863%
SRNE
1.95
-0.15
-7.14%
TROV
0.93
+0.02
+2.46%
VICL
2.36
+0.05
+2.16%
VOLC
18
0.00
0.00%
ZGNX
11
0.00
0.00%
Home » Archive by Category

Syndication

Tech Transaction Attorney – 5 plus years – Wegman Partners LLC – San Diego, CA

April 27, 2017 – 10:23 pm

Essential skills include exceptional written and verbal communication, attention to detail, good judgment, a team-oriented attitude, solid interpersonal and…From Wegman Partners LLC – Fri, 28 Apr 2017 06:23:12 GMT – View all San Diego jobs

Senior Accountant – Proven Inc. – San Diego, CA

April 27, 2017 – 5:08 pm

Please send your resume to April Ayyoubi at aayyoubi@provenrecruiting.com if you have the requisite experience for this opportunity and are looking to wear many…From Proven Inc. – Fri, 28 Apr 2017 01:08:41 GMT – View all San Diego jobs

Aspyrian announces the presentation of clinical data of its investigational therapy RM-1929 demonstrating significant anti-cancer response in recurrent Head and Neck Cancer patients who have failed all existing treatment options

April 27, 2017 – 4:00 pm

Data from patients treated at Thomas Jefferson University demonstrates high response rate and good safety in second line of head and neck cancerEvidence of tumor necrosis post treatment observed in all patients treatedRegistration trials expected to begin in the first half of 2018

SAN DIEGO, April 27, 2017 /PRNewswire/ — Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy (PIT) platform, today announced that findings from an ongoing clinical trial of its proprietary investigational compound, RM-1929, were presented at the American Head & Neck Society meeting, April 27, in San Diego.

The data presented are from a multicenter trial of PIT with RM-1929 for patients with recurrent head and neck squamous cell carcinoma that cannot be satisfactorily treated with surgery, radiation or platinum chemotherapy. The data are from seven patients enrolled at Thomas Jefferson University, Philadelphia, PA. The Principal Investigator, Dr. David Cognetti, and his team described the clinical outcomes in patients treated with repeated cycles of PIT with RM-1929. Each treatment consisted of a single drug infusion of RM-1929, followed by light activation of the drug at the tumor at 24-hour post infusion. If persistent disease was present at 4 weeks, the patient could progress into a subsequent treatment cycle.

The investigators noted, “Targeted photoimmunotherapy using a conjugate of cetuximab and IR700 dye is safe and well tolerated and led to evidence of tumor necrosis at the treatment site in 7/7 (100%) patients. No skin photosensitivity or normal tissue toxicity noted. Four out of 7 (57%) patients had durable clinical response to the treatment without progression of disease.”

“It is truly extraordinary how dramatic and rapid the tumor response to RM-1929 Photoimmunotherapy has been on cancers that have been recurrent and resistant to all therapies, while also being well tolerated by the patients.  None of the patients have had any light sensitivities or other systemic side effects, which is a major limitation of other traditional cancer treatment modalities. said Dr. David Cognetti, M.D., Associate Professor, Co-Director, Jefferson Center for Head and Neck Surgery, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA.

“This is a remarkable treatment outcome for head and neck cancer patients who have failed all previous standard of care therapies and have no viable therapeutic options available to them.”   said Dr. Merrill Biel, M.D. Ph.D., Chief Medical Officer of Aspyrian. “These first in human clinical data support the potential for RM-1929 Photoimmunotherapy to uniquely provide a viable option to control this disease while preserving normal healthy tissues in the head and neck area that are so critical to maintaining the patient’s quality of life and we look forward to the ongoing clinical trial results.”

“In less than two years after initiating clinical studies of RM-1929, we have rapidly gained a good understanding of the safety and anticancer potential of Photoimmunotherapy with RM-1929. Given the significant results so far, we are fully committed to drive this therapy to the market as fast as possible and we intend to initiate the first registration trials in early 2018.” said Miguel Garcia-Guzman, Ph.D., President and CEO at Aspyrian. “We intend to develop Photoimmunotherapy with RM-1929 as a single agent and as a combination treatment to provide the best possible outcomes for recurrent head and neck cancer patients, both in the first-line and-second line settings. In addition, we expect to initiate further phase 2 proof-of-concept studies in other EGFR expressing cancer types sometime in the second half of 2018. I congratulate our outstanding team at Aspyrian and our excellent clinical collaborators, particularly Dr. Cognetti, for their exceptional work and commitment to provide cancer patients with better options to conquer their disease”.

About RM-1929

RM-1929, a conjugate of Cetuximab and IRDye 700DX®, targets epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck squamous cell carcinomas, esophagus, lung, colon, and pancreas. This first-in-class therapy uses an antibody conjugate to precisely target cancer cells after which it is locally activated with red light to elicit rapid anti-cancer responses. The dual specificity resulting from local activation of a tumor-selective conjugate promises to deliver oncologists the ability to achieve locoregional tumor control with minimal damage to surrounding healthy tissues and structures.

RM-1929 is an investigational compound that is not approved for any use in any country.

For more information on the clinical trial, please follow this link to the study record on ClinicalTrials.gov: 
Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer

About Aspyrian Therapeutics Inc.
Aspyrian Therapeutics, Inc., is a privately funded clinical stage biotechnology company developing a new class of precision targeted oncologic drugs for the treatment of solid tumors based on the PIT platform licensed from the National Cancer Institute (NCI).

Aspyrian has secured the exclusive license to use IRDye 700DX® from LI-COR (Lincoln, Nebraska) for development of PIT products. The Company is currently working with a number of monoclonal antibodies with the potential to treat various types of cancers, including head and neck, esophageal, lung, brain, pancreatic, colorectal, breast and ovarian. 

 

SOURCE Aspyrian Therapeutics Inc.

Document Control Specialist II – Invivoscribe Technologies, Inc. – San Diego, CA

April 27, 2017 – 2:37 pm

Customers include many of the world’s leading pharmaceutical and biotechnology companies, medical centers, cancer research centers, reference laboratories and…
From Indeed – Thu, 27 Apr 2017 22:37:07 GMT – View all San Diego jobs

Quality Control Lab Assistant

April 27, 2017 – 1:59 pm

Duties and responsibilities:
• Sample all incoming raw materials and returned products
• Inspect and perform testing on incoming raw materials
• Perform in-process testing on products
• Assist chemists by performing sample preparation
? […]

Medical Director, Oncology Clinical Development – Halozyme Therapeutics, Inc. – San Diego, CA

April 27, 2017 – 1:10 pm

Minimum of (4+) years of clinical research experience in oncology within biotechnology, biopharmaceutical, and/or pharmaceutical companies within a similar role…From Halozyme Therapeutics, Inc. – Thu, 27 Apr 2017 21:10:32 GMT – View all San Diego jobs

SENOMYX ANNOUNCES FIRST QUARTER 2017 FINANCIAL RESULTS

April 27, 2017 – 12:15 pm

SAN DIEGO, April 27, 2017 /PRNewswire/ — Senomyx, Inc. (NASDAQ: SNMX), a leading company using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients and natural high intensity sweeteners for the food, beverage, and ingredient supply industries, today reported financial results for the first quarter ended March 31, 2017.

Highlights from the first quarter include:

  • Commercial revenues increased 26% and direct sales increased 250% over the first quarter of 2016
  • Natural high intensity sweetener, siratose, introduced
  • Regulatory authorization received for commercialization of a new cooling flavor ingredient

“Senomyx is off to a good start in 2017,” stated John Poyhonen, President and Chief Executive Officer of the Company. “We exceeded our financial guidance for the first quarter of 2017 and are well-positioned to meet key commercial revenue, business development and R&D goals. During the first quarter, we grew direct sales to well over twice that of our previous highest quarter, we advanced business development discussions on siratose, our lead natural high intensity sweetener, and we received regulatory authorization to commercialize a new cooling flavor ingredient.”

Operational Results:

In March, the Company introduced its new natural high intensity sweetener under the common or usual name of siratose and made important disclosures related to the plant source, the expected manufacturing process and anticipated development timeline for siratose. The siratose disclosures have facilitated the Company’s pursuit of new non-exclusive collaborative relationships for its natural sweet taste program that maximize the commercial potential and provide its collaborators with access to siratose and future natural product discoveries. “We have built a pipeline of about 20 excellent collaboration candidates and we remain confident in our ability to begin adding collaborators to our syndicate during 2017,” stated Poyhonen.

“On the development front, our newest cooling flavor ingredient, Coolmyx CL19, was determined Generally Recognized As Safe (GRAS) by the Expert Panel of the Flavor and Extract Manufacturers Association of the United States (FEMA) during the first quarter. The GRAS determination allows Senomyx to pursue commercialization in the U.S. and a number of other countries.  Coolmyx CL19 provides a clean, long lasting cooling taste profile and we will initially pursue beverages, confectionary, and oral healthcare products as the target market. Third parties are currently evaluating this cooling flavor and we are considering a broad range of strategic options for commercialization,” Poyhonen concluded.

“Direct sales of Senomyx’s Complimyx® flavor ingredient offerings grew to record levels during the first quarter with revenues increasing by over 250% compared to the same quarter of the prior year,” stated Sharon Wicker, Senior Vice President and Chief Commercial Development Officer. “We continue to earn new business with world-class flavor house customers and their forecasts for future use of our flavor ingredients is promising. During the first quarter, we announced that we had filled a newly created position, senior director of sales, to lead our sales organization in the field and we have added an experienced flavor ingredient broker with a proven track record to represent Senomyx in Asia and Oceania. We remain enthusiastic about the positive impact we anticipate these steps will have on our direct sales efforts going forward.”

Financial Results:

Commercial revenues increased 26% to $2.6 million in the first quarter ended March 31, 2017. This improvement primarily resulted from higher direct sales of flavor ingredients to flavor houses and higher royalties from sweet taste boosting ingredients. These increases were partially offset by a $500,000 one-time commercial milestone earned in the first quarter of 2016 related to the cooling taste program.

Development revenues decreased to $1.8 million in the first quarter ended March 31, 2017. This decrease was primarily due to the July 2016 contractual conclusion of the research and development funding period under the sweet taste program collaboration with Firmenich.

Research, development and patent expenses decreased $1 million to $4.4 million for the first quarter ended March 31, 2017. The reduction in expenses is primarily due to lower personnel-related expenses partially offset by higher outsourced development activities associated with Sweetmyx® FS22, the Company’s next generation sweet taste booster. Selling, general and administration expenses were consistent with prior year at $3.1 million for the first quarter ended March 31, 2017. Included in these first quarter 2017 R&D and SG&A expenses were approximately $800,000 in non-cash, stock-based compensation expenses.

The net loss for the first quarter 2017 was $3.4 million or $0.07 per share.

Senomyx ended the first quarter 2017 with no debt and $10.1 million in cash. Accounts payable decreased by $1.4 million during the first quarter. At the end of the first quarter, the Company had $5.5 million in accounts receivable, of which $5.0 million is anticipated to be received during the second quarter.  In addition to these accounts receivable amounts, the Company is currently scheduled to receive $15.8 million in committed development funding in the future. 

Second Quarter 2017 Outlook:

For the second quarter of 2017, the Company expects:

  • Revenues to be at least $4.6 million, of which at least $2.7 million are commercial revenues; and
  • Net loss not to exceed $3.3 million or $0.07 per share

Conference Call:

Senomyx will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) Thursday, April 27, 2017 to discuss these financial results and provide an update on the Company. To participate in the live conference call, U.S. residents should dial (844) 825-0514, and international callers should dial (315) 625-6892, at least 10 minutes prior to the call start time. The conference ID for this call is 97603082.

To access the live Internet broadcast or a subsequent archived recording, please log onto the Investor Relations section of Senomyx’s website at http://investor.senomyx.com.

About Senomyx, Inc. (www.senomyx.com)

Senomyx discovers novel flavor ingredients and natural high intensity sweeteners that allow food and beverage companies to create better-for-you products. Under its direct sales program, Senomyx sells its Complimyx® brand flavor ingredients, Sweetmyx®, Savorymyx®, and Bittermyx®, to flavor companies for use in a wide variety of foods and beverages. In addition, Senomyx has partnerships with leading global food, beverage, and ingredient supply companies, which are currently marketing products that contain Senomyx’s flavor ingredients. For more information, please visit www.senomyx.com.

Forward-Looking Statements:

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, regarding our projected financial results and anticipated financial condition in 2017, statements regarding new collaboration agreements and the anticipated funding we may receive, whether the research under our natural sweet taste research program will be successful and lead to the commercialization of any new flavor ingredients or natural high intensity sweeteners and the anticipated timing and scope of commercial launch of products containing our flavor ingredients, whether by our collaborators or through our direct sales program. Risks that contribute to the uncertain nature of the forward-looking statements include: large companies such as PepsiCo and Firmenich are typically conservative when implementing changes to their branded products, and may not begin or expand their use of our flavor ingredients when expected or at all; we are substantially dependent on our current and any future product discovery and development collaborators to develop and commercialize any flavor ingredients we may discover; we are dependent on our current and any future product discovery and development collaborators for our research and development funding; we may not successfully grow our direct sales program; commercial launches of new or reformulated food, beverage and ingredient products incorporating our flavor ingredients may not occur when expected or at all; the commercial utility for a novel flavor ingredient that we develop may ultimately be more limited than we expected; the cost to manufacture and/or formulate any of our flavor ingredients into packaged food and beverage products may be higher than anticipated, which could discourage market entry and acceptance; development activities for newer flavor ingredients may not demonstrate an acceptable safety profile or meet other commercialization criteria; no assurance can be given that we will be successful in developing and bringing to market novel natural high intensity sweeteners; and we may face challenges and delays in developing manufacturing pathways to supply novel natural high intensity sweeteners at a competitive cost and in obtaining requisite regulatory approval. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, under the headings “Risks Related to Our Business” and “Risks Related to Our Industry.” All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Financial Information to Follow)

Contact:
Tony Rogers
Senior Vice President & Chief Financial Officer
Senomyx, Inc.
858-646-8304
tony.rogers@senomyx.com

 

Selected Financial Information

Condensed Statements of Operations

(in thousands, except for per share amounts)

Three Months
Ended March 31,

2017

2016

(unaudited)

(unaudited)

Revenues:

Development revenues

$

1,846

$

4,178

Commercial revenues

2,620

2,072

Total revenues

4,466

6,250

Operating expenses:

    Cost of commercial revenues

421

220

Research, development and patents (including $297 and $502, respectively,
of non-cash stock-based compensation)

4,427

5,432

Selling, general and administrative (including $496 and $648, respectively,
of non-cash stock-based compensation)

3,066

3,036

Total operating expenses

7,914

8,688

Loss from operations

(3,448)

(2,438)

Other income

12

19

Net loss

$

(3,436)

$

(2,419)

Basic and diluted net loss per share

$

(0.07)

$

(0.05)

Weighted average shares used in computing basic and diluted net loss per share

45,842

44,597

 

Condensed Balance Sheets

(in thousands)

March 31,
2017

December 31,
2016

(unaudited)

Cash, cash equivalents and investments available-for-sale

$

10,148

$

12,363

Other current assets

8,468

8,670

Property and equipment, net

2,874

2,731

Total assets

$

21,490

$

23,764

Accounts payable, accrued expenses and other current liabilities

$

4,138

$

5,490

Deferred revenues

10

14

Deferred rent

1,743

1,886

Leasehold incentive obligation

1,517

1,572

Stockholders’ equity

14,082

14,802

Total liabilities and stockholders’ equity

$

21,490

$

23,764

 

 

SOURCE Senomyx, Inc.

Payroll & A/R Clerk – Ensunet Consulting Corporation – San Diego, CA

April 27, 2017 – 12:06 pm

Ensunet Technology Group provides superior technology professional services for Biotechnology, Healthcare, and Government agencies in the areas of strategic…From Monster – Thu, 27 Apr 2017 20:06:46 GMT – View all San Diego jobs

Project Manager – Illumina, Inc. – San Diego, CA

April 27, 2017 – 11:09 am

Ensure our product development efforts adhere to the product development process and design control standards….From Illumina, Inc. – Thu, 27 Apr 2017 19:09:32 GMT – View all San Diego jobs

Manufacturing Engineer – Lasergen, Inc. – San Diego, CA

April 27, 2017 – 9:03 am

Is an emerging biotechnology company focused on commercializing novel technologies for DNA sequencing. Our expertise in nucleotide chemistry and next-generation…From Indeed – Thu, 27 Apr 2017 17:03:13 GMT – View all San Diego jobs